Glycopyrronium 320 μg/mL in children and adolescents with severe sialorrhoea and neurodisabilities: A randomized, double-blind, placebo-controlled trial.
Pierre FayouxMickael DinomaisHelen ShawFrédéric VillainDéborah SchwartzStéphane RondeauGuy LetellierStėphane AuvinPublished in: Developmental medicine and child neurology (2024)
The formulation of 320 μg/mL glycopyrronium significantly improved drooling and reduced its impact on QoL, with good tolerability in children with neurodisabilities.